C-MER Medical Holdings Limited
希瑪醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

POSITIVE PROFIT ALERT

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of C-MER Medical Holdings Limited (the "**Company**" which together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the unaudited financial information currently available for the year ended 31 December 2025 ("**FY2025**"), the Company is expected to realise a turnaround and achieve a profit attributable to the equity holders of the Company in the range of HK$90.0 million to HK$110.0 million, as compared with a loss attributable to equity holders of HK$135.2 million for the year ended 31 December 2024 ("**FY2024**").

The expected increase in profit attributable to equity holders of the Company was primarily driven by (i) the slight increase in revenue to approximately HK$1,947.0 million in FY2025 from HK$1,913.2 million in FY2024, (ii) the effectiveness of our strategies to optimise our service network and enhance operating efficiency, which included the closure of non-performing operations, and (iii) no material impairment loss recorded on non-current assets in FY2025, compared to an impairment loss of HK$197.7 million recorded in FY2024.

As the Company is still in the process of finalising the results for FY2025, the information contained in this announcement is based on the management's preliminary review of the management accounts of the Group and current information available to the Board and has not been audited and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the annual results announcement of the Company for FY2025 which is expected to be published by the end of March 2026.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Medical Holdings Limited
Ms. LI Xiaoting
Vice Chairman, Executive Director and Chief Executive Officer

Hong Kong, 6 March 2026

As at the date of this announcement, the Board comprises its chairman and independent non-executive Director, Dr. Rex AUYEUNG Pak-kuen; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.